Expression of VEGF and VEGF receptors in childhood precursor B-cell Acute lymphoblastic leukemia evaluated by immunohistochemistry

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 9, 2009, Pages 696-701

  Diffner, Eva ^a   Gauffin, Fredrika ^b   Anagnostaki, Lola ^c   Nordgren, Ann ^d   Gustafsson, Bertil ^e   Sander, Birgitta ^f   Gustafsson, Britt ^b   Persson, Jenny Liao ^a  

^a LUND UNIVERSITY   (Sweden)

^b Department of Clinical Science Intervention and Technology ^*

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Childhood pre B ALL; Immunohistochemistry; VEGF; VEGFR 1; VEGFR 2

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; PRE B LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; STEM CELL; TISSUE MICROARRAY;

ADOLESCENT; BONE MARROW; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; MALE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 70349113909     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181b258df     Document Type: Article

References (32)

1. Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol. 2009;46:52-63.
2. Pulte D, Gondos A, Brenner H. Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004. J Natl Cancer Inst. 2008;100:1301-1309.
3. Podar K, Anderson KC. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 2005;105:1383-1395.
4. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood. 2004;103:3883-3889.
5. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.
6. Shibuya M. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res. 1995;67:281-316.
7. Gerber HP, Malik AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002;417:954-958.
8. Aguayo A, O'Brien S, Keating M, et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood. 2000;96:768-770.
9. Zhang Y, Pillai G, Gatter K, et al. Expression and cellular localization of vascular endothelial growth factor A and its receptors in acute and chronic leukemias: an immunohistochemical study. Hum Pathol. 2005;36:797-805.
10. Kalmanti L, Dampaki K, Dimitriou H, et al. A morphometric approach for the evaluation of angiogenesis in acute lymphoblastic leukemia of childhood. Leuk Res. 2005;29:673-677.
11. Perez-Atayde AR, Sallan SE, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815-821.
12. Matuszewski L, Persigehl T, Wall A, et al. Assessment of bone marrow angiogenesis in patients with acute myeloid leukemia by using contrast-enhanced MR imaging with clinically approved iron oxides: initial experience. Radiology. 2007;242:217-224.
13. Kuzu I, Beksac M, Arat M, et al. Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival. Leuk Lymphoma. 2004;45:1185-1190.
14. Lee JJ, Chung IJ, Park MR, et al. Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia. Leuk Res. 2001;25:1067-1073.
15. de Bont ES, Rosati S, Jacobs S, et al. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol. 2001;113:296-304.
16. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95:309-313.
17. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637-2644.
18. Rabitsch W, Sperr WR, Lechner K, et al. Bone marrow microvessel density and its prognostic significance in AML. Leuk Lymphoma. 2004;45:1369-1373.
19. El-Obeid A, Sunnuqrut N, Hussain A, et al. Immature B cell malignancies synthesize VEGF, VEGFR-1 (Flt-1) and VEGFR-2 (KDR). Leuk Res. 2004;28:133-137.
20. Koomagi R, Zintl F, Sauerbrey A, et al. Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res. 2001; 7:3381-3384.
21. Lyu CJ, Rha SY, Won SC. Clinical role of bone marrow angiogenesis in childhood acute lymphocytic leukemia. Yonsei Med J. 2007;48:171-175.
22. Yetgin S, Yenicesu I, Cetin M, et al. Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2001;42:83-88.
23. Schneider P, Vasse M, Corbiere C, et al. Endostatin variations in childhood acute lymphoblastic leukaemia-comparison with basic fibroblast growth factor and vascular endothelial growth factor. Leuk Res. 2007;31:629-638.
24. Aref S, Salama O, Shamaa S, et al. Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia. Hematology. 2007;12:319-324.
25. Faderl S, Do KA, Johnson MM, et al. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood. 2005;106:4303-4307.
26. Kharfan-Dabaja MA, Patel SA, Osunkoya AO, et al. Expression of the vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia: incidence and feasibility of immunohistochemical staining. Clin Lab Haematol. 2006;28: 254-258.
27. Fragoso R, Pereira T, Wu Y, et al. VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood. 2006;107:1608-1616.
28. Padro T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia. 2002;16:1302-1310.
29. Wu S, Gessner R, von Stackelberg A, et al. Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic leukemia: correlation of expression and clinical outcome at first disease recurrence. Cancer. 2005;103:1054-1063.
30. Stachel D, Albert M, Meilbeck R, et al. Expression of angiogenic factors in childhood B-cell precursor acute lymphoblastic leukemia. Oncol Rep. 2007;17:147-152.
31. Wellmann S, Guschmann M, Griethe W, et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia. 2004;18:926-933.
32. Wellwood J, Taylor K. Central nervous system prophylaxis in haematological malignancies. Intern Med J. 2002;32:252-258.